Does Blue Cross Blue Shield of Michigan Cover Eliquis?

How BCBSM Classifies Eliquis on Its Formulary

Blue Cross Blue Shield of Michigan places Eliquis (apixaban) on the preferred-brand tier across the majority of its plan types. This means the drug is covered but carries a higher copay than generic alternatives like warfarin. BCBSM updates its formulary quarterly, so tier placement can shift at renewal.

Commercial Plan Tiers

On standard BCBSM commercial PPO and HMO plans, Eliquis generally falls on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). The distinction depends on the employer group's negotiated formulary. Tier 2 placement typically means a copay between $30 and $50 per fill. Tier 3 placement pushes that range to $50 to $90, or in some coinsurance-based designs, 25% to 35% of the drug's retail cost.

Blue Care Network (BCN) Plans

Blue Care Network, the HMO arm of BCBSM, maintains its own formulary. Eliquis appears on BCN's preferred-brand tier with similar cost-sharing to commercial PPO plans. BCN members should verify their specific benefit booklet, since small-group and individual-market BCN plans occasionally differ in tier structure.

Medicare Advantage Formularies

BCBSM Medicare Advantage (Medicare Plus Blue) plans cover Eliquis, though cost-sharing follows the Medicare Part D benefit structure. During the initial coverage phase, members may pay a copay of $42 to $100 per month. Once the $2,000 true out-of-pocket threshold is reached (for the 2026 benefit year), catastrophic coverage begins and costs drop to $0 or a small copay under the Inflation Reduction Act cap 1.

What Eliquis Costs with BCBSM Insurance

The retail price of Eliquis without insurance runs approximately $550 to $620 for a 30-day supply of the standard 5 mg twice-daily dose. Insurance brings that figure down substantially, but the exact amount depends on your plan design.

Copay vs. Coinsurance Structures

Some BCBSM plans use flat copays (a fixed dollar amount per fill). Others use coinsurance (a percentage of the drug's negotiated price). A flat copay of $45 is predictable. A 30% coinsurance on a $550 drug is $165, a much higher figure. Checking your Summary of Benefits and Coverage document reveals which structure your plan uses.

How the Manufacturer Savings Card Works

Bristol-Myers Squibb and Pfizer jointly offer the Eliquis 360 Support savings card. Eligible commercially insured patients can reduce their copay to as low as $10 per month, with an annual maximum benefit. The card does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA). Patients can enroll at the manufacturer's website or by calling the number on the Eliquis prescribing information 2.

Comparing Out-of-Pocket Costs Across Plan Types

| Plan Type | Typical Monthly Cost | Notes | |---|---|---| | BCBSM Commercial PPO (Tier 2) | $30 to $50 copay | Savings card may reduce to $10 | | BCBSM Commercial PPO (Tier 3) | $50 to $90 copay | Savings card may reduce to $10 | | Blue Care Network HMO | $35 to $60 copay | Verify BCN-specific formulary | | Medicare Plus Blue (initial phase) | $42 to $100 copay | IRA $2,000 OOP cap applies | | Medicare Plus Blue (catastrophic) | $0 to small copay | After $2,000 TrOOP threshold |

Prior Authorization and Step Therapy Rules

BCBSM does not require prior authorization for Eliquis when prescribed for its two primary FDA-approved indications: reducing stroke risk in nonvalvular atrial fibrillation and treating or preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) 3.

When Prior Auth May Be Required

Prior authorization can apply when Eliquis is prescribed for off-label uses or when the diagnosis code submitted does not match standard AFib or VTE indications. In those situations, BCBSM's pharmacy benefit manager reviews the clinical documentation before approving coverage.

Step Therapy Protocols

Certain BCBSM plans, particularly some employer-sponsored group designs, impose step therapy. This means the patient must have tried and failed (or have a documented contraindication to) warfarin before Eliquis is approved. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily was superior to warfarin for preventing stroke in atrial fibrillation, with a 21% reduction in stroke or systemic embolism (HR 0.79, 95% CI 0.66 to 0.95) and a 31% reduction in major bleeding 4. Your prescriber can cite this evidence in a step-therapy exception request.

Quantity Limits

BCBSM applies quantity limits consistent with FDA-approved dosing. The standard quantity allowed is 60 tablets per 30-day supply (two tablets daily). The reduced dose of 2.5 mg twice daily, used in patients meeting at least two of three criteria (age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher), also receives coverage at 60 tablets per 30 days 5.

Why Physicians Prescribe Eliquis Over Warfarin

Apixaban belongs to the direct oral anticoagulant (DOAC) class, which has largely replaced warfarin as first-line therapy for nonvalvular atrial fibrillation. The shift is backed by a substantial evidence base showing better safety profiles and comparable or superior efficacy.

Clinical Trial Evidence

The ARISTOTLE trial remains the landmark study. Published in the New England Journal of Medicine, it randomized 18,201 patients with atrial fibrillation and at least one additional stroke risk factor to apixaban 5 mg twice daily or dose-adjusted warfarin. Apixaban reduced the rate of stroke or systemic embolism by 21% (1.27% vs. 1.60% per year, P<0.001 for noninferiority, P=0.01 for superiority). All-cause mortality also favored apixaban (3.52% vs. 3.94% per year, P=0.047) 4.

For VTE treatment, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE, with significantly less major bleeding (0.6% vs. 1.8%, relative risk 0.31, P<0.001) 6.

Guideline Recommendations

The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) 2019 guideline update for management of atrial fibrillation recommends DOACs over warfarin for eligible patients with nonvalvular AFib (Class I recommendation) 7. Dr. Craig January, lead author of the 2014 ACC/AHA/HRS AF guideline, stated: "For patients with atrial fibrillation who are appropriate for anticoagulation, DOACs are preferred over warfarin, except in patients with moderate-to-severe mitral stenosis or mechanical heart valves."

The American College of Chest Physicians (ACCP) CHEST guideline similarly recommends DOACs over vitamin K antagonists for VTE treatment in patients without cancer (Grade 2B recommendation) 8.

How to Check Your Specific BCBSM Coverage

Not all BCBSM plans are identical. Employer groups negotiate custom formularies, and individual-market plans differ from group coverage.

Steps to Verify Your Benefits

1. Log in to your BCBSM member portal or the Blue Cross Blue Shield of Michigan mobile app.
2. Manage to the "Pharmacy" or "Drug Coverage" section.
3. Search for "apixaban" or "Eliquis" in the formulary lookup tool.
4. Note the tier, copay or coinsurance, and any utilization management flags (prior auth, step therapy, quantity limits).
5. Call the member services number on the back of your insurance card if the online tool does not show your specific plan's details.

Requesting a Formulary Exception

If your BCBSM plan denies Eliquis coverage or places it on a higher tier than expected, you and your prescriber can file a formulary exception request. This requires clinical documentation explaining why Eliquis is medically necessary and why alternatives (like warfarin or rivaroxaban) are not appropriate. BCBSM must respond to standard exception requests within 72 hours and urgent requests within 24 hours for Medicare Advantage plans, per CMS regulations 9.

What to Do If You Are Denied

If the exception is denied, you can appeal. The internal appeal goes to a clinical reviewer not involved in the original decision. If the internal appeal is also denied, Medicare Advantage members have the right to an independent external review through an Independent Review Entity (IRE). Commercial plan members in Michigan can file a complaint with the Michigan Department of Insurance and Financial Services (DIFS).

Eliquis Safety Profile and Monitoring on BCBSM Plans

BCBSM covers the lab work associated with Eliquis monitoring, though the drug itself requires less frequent monitoring than warfarin.

Monitoring Differences: Eliquis vs. Warfarin

Warfarin requires regular INR (international normalized ratio) blood tests, often weekly during initiation and at least monthly thereafter. Eliquis does not require routine coagulation monitoring. However, prescribers typically check baseline renal function (serum creatinine, eGFR) and hepatic function before initiating therapy, then annually or when clinical status changes 10.

Renal Dose Adjustment

The reduced dose of apixaban 2.5 mg twice daily applies to patients meeting two or more of these criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. The ARISTOTLE trial included patients with creatinine clearance as low as 25 mL/min. Apixaban is not recommended in patients on dialysis, though limited data from pharmacokinetic studies exist 5.

Bleeding Risk Management

The overall rate of major bleeding with apixaban in ARISTOTLE was 2.13% per year compared with 3.09% per year for warfarin (HR 0.69, P<0.001). Intracranial hemorrhage occurred at 0.33% per year with apixaban vs. 0.80% per year with warfarin 4. Dr. Renato Lopes, a co-investigator on ARISTOTLE and professor at Duke University, noted: "The reduction in intracranial hemorrhage with apixaban compared to warfarin is one of the most clinically meaningful findings, as this type of bleeding carries high mortality and disability rates."

BCBSM covers andexanet alfa (Andexxa), the FDA-approved reversal agent for apixaban, under the medical benefit for hospital-administered infusions. This coverage is limited to life-threatening or uncontrolled bleeding emergencies 11.

Alternatives If Eliquis Is Not Covered or Too Expensive

If your BCBSM plan does not cover Eliquis at an affordable tier, several alternatives exist within the DOAC class and beyond.

Other DOACs on BCBSM Formularies

Rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) are also covered on most BCBSM formularies. Rivaroxaban was studied in the ROCKET AF trial (N=14,264), where it was noninferior to warfarin for stroke prevention (HR 0.88, P<0.001 for noninferiority) but did not achieve superiority in the intention-to-treat analysis 12. Dabigatran, evaluated in RE-LY (N=18,113), showed that the 150 mg twice-daily dose was superior to warfarin for stroke prevention (RR 0.66, P<0.001) but with a higher rate of gastrointestinal bleeding 13.

Warfarin as a Lower-Cost Option

Generic warfarin costs $4 to $15 per month at most Michigan pharmacies. For patients whose primary barrier is cost and who can manage regular INR monitoring, warfarin remains an effective option with decades of clinical experience. The trade-off is more frequent lab visits, dietary interactions with vitamin K, and the narrower therapeutic window.

Patient Assistance Programs

Patients who are uninsured or underinsured may qualify for the Bristol-Myers Squibb Patient Assistance Foundation, which provides Eliquis at no cost to eligible individuals. Income thresholds typically require household income at or below 300% of the federal poverty level.

Key Takeaways for Michigan Patients

BCBSM covers Eliquis on the vast majority of its plans. Most patients with nonvalvular atrial fibrillation or VTE will obtain coverage without prior authorization. Use the manufacturer copay card if you carry commercial insurance to bring monthly costs to $10 or less, and verify your specific plan's formulary through the BCBSM member portal before filling your prescription.